Retrospective studies have found an unexpectedly high incidence of hepatocellular carcinoma (HCC) among patients with CHC-associated cirrhosis who received DAA therapy39, as compared to those who achieved SVR with interferon-based regimens (IFN-SVR). The gene discussed is IFNA1; the disease is Cirrhosis.